History of the Former Yamanouchi Pharmaceutical Co., Ltd.

1923
Kenji Yamanouchi founded Yamanouchi Yakuhin Shokai in Osaka.
Changed the name to Yamanouchi Pharmaceutical Co., Ltd. in 1940, Moves the head office to Tokyo in 1942
1970
Launched antibiotic drug "Josamycin"
1981
Launched "Perdipine," an agent for the treatment of hypertension
1985
Launched "Gaster," an H2 reseptor antagonist diseases/gastritis
Currently sold in more than 100 countries
1986
Established Yamanouchi Ireland Co., Ltd. in Europe
The first overseas production base for active pharmaceutical ingredients
1989
Tsukuba laboratory completed
1990
Acquired the pharmaceutical division of Royal Gist Brocades (Netherlands)
1993
Launched "Harnal"
Currently sold in more than 90 countries
1994
Established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China
2000
Launched "Lipitor," an agent to treat hypercholesterolemia
2001
Established Yamanouchi Pharma America, Inc. in the U.S.
Sales base of the company in the U.S.
2004
Launched "Vesicare," an agent for overactive bladder treatment, in Europe
Launched in the U.S. as well in 2005
OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.
2005
Apr. 1, 2005 Astellas Pharma Inc. was established

 

History of the Former Fujisawa Pharmaceutical Co., Ltd.

1894
Tomokichi Fujisawa founded Fujisawa Shoten in Osaka
1897
Launched "Fujisawa Camphor" as a home-use insect repellent
1943
Changed the company name to Fujisawa Pharmaceutical Co., Ltd.
1964
Central Laboratory completed
1971
Launched "Cefamezin," an antibiotic for injections
Proceeds to market it worldwide.
1977
Established Fujisawa Pharmaceutical Corp. in the U.S.
The company's first business base in the U.S.
1979
Opened a London Office, the company's first business base in Europe
1983
Tsukuba Laboratory completed
1991
Established Fujisawa Europe GmbH in Germany
1993
Launched immunosuppressant "Prograf"
Currently sold in about 100 countries
1998
Restructured the business in the U.S., founds Fujisawa Healthcare, Inc.
1999
Launched "Protopic," an agent to treat atopic dermatitis
Currently sold in about 60 countries
2004
OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.
2005
Apr. 1, 2005 Astellas Pharma Inc. was established

 

History of Astellas Pharma Inc.

May 2005
Launched "Mycamine," an intravenous candin antifungal agent
Apr. 2006
Launched "Vaprisol," an agent for the treatment of hyponatremia, in the U.S.
Sold Zephama shared to Daiichi Sankyo Co., Ltd.
Jun. 2006
Launched "Vesicare", an agent for overactive bladder treatment, in Japan
Jun. 2007
Launched immunosuppresant "Advagraf" in Europe
Nov. 2007
Acquired Agensys, Inc
Oct. 2008
Completed the New Buildings in the Tsukuba Research Center
Apr. 2009
Launched "Bonoteo Tablets" in Japan for the Osteoporosis Treatment
Nov. 2009
Launched "VIBATIV (telavancin)" in the United States
Jan. 2010
Launched "Symbicort Turbuhaler" in Japan for the treatment of Adult Bronchial Asthma
Jun. 2010
Acquired OSI Pharmaceuticals
Sep. 2011
Launched "Betanis Tablet" in Japan for the treatment of overactive bladder (OAB)
Jun. 2012
Launched "DIFICLIR" in Europe for the treatment of adults with Clostridium difficile infections (CDI)
Launched "Kiklin Capsules" in Japan for the treatment for Hyperphosphatemia
Jul. 2012
Launched "Regnite Tablets" in Japan for Restless Legs Syndrome
Sep. 2012
Launched "XTANDI (enzalutamide)" in the U.S. for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel
Oct. 2012
Launched "Gonax (Degarelix Acetate)" for Subcutaneous Injection in Japan for Treating Prostate Cancer
Launched "MYRBETRIQ (mirabegron)" in the U.S. for the treatment of overactive bladder (OAB)
Jan. 2013
Launched "ARGAMATE" in Japan for the treatment of Hyperkalemia
Mar. 2013
Launched "Cimzia (certolizumab pegol)" in Japan for the treatment of adult patients with rheumatoid arthritis
Apr. 2013
Relocated Global HQ building in Tokyo
Jun. 2013
Launched "Acofide" in Japan for Treating Functional Dyspepsia
Aug. 2013
Launched "ASTAGRAF XL (tacrolimus extended-release capsules)" in the U.S.
Apr. 2014
Launched "Suglat Tablets", a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes
May. 2014
Launched "XTANDI (enzalutamide) Capsules" in Japan for Prostate Cancer Treatment